Page last updated: 2024-11-07

inositol cyclic phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Inositol cyclic phosphate (Ins(1,4,5)P3 or IP3) is a second messenger molecule that plays a crucial role in intracellular signaling pathways. It is produced by the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) by the enzyme phospholipase C (PLC). IP3 binds to specific receptors on the endoplasmic reticulum (ER) membrane, triggering the release of calcium ions (Ca2+) from intracellular stores. This calcium release is critical for a wide range of cellular processes, including muscle contraction, neurotransmitter release, and gene expression. IP3 is studied extensively for its role in various physiological and pathological processes, including cell growth, development, inflammation, and cancer. Its synthesis is tightly regulated, and its levels are influenced by factors such as hormones, neurotransmitters, and growth factors.'

inositol cyclic phosphate: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1D-myo-inositol 1,2-cyclic phosphate : A myo-inositol cyclic phosphate that is the 1,2-cyclic phosphate derivative of 1D-myo-inositol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID122331
CHEBI ID18426
MeSH IDM0055529

Synonyms (15)

Synonym
CHEBI:18426 ,
myo-inositol 1,2-cyclic phosphate
1d-myo-inositol 1,2-(hydrogen phosphate)
inositol cyclic phosphate
C04299
43119-57-9
d-myo-inositol 1,2-cyclic phosphate
1d-myo-inositol 1,2-cyclic phosphate
(3as,4r,5s,6s,7r,7ar)-2-hydroxy-2-oxo-3a,4,5,6,7,7a-hexahydrobenzo[d][1,3,2]dioxaphosphole-4,5,6,7-tetrol
inositol cyclic-1,2-monophosphate
myo-inositol, cyclic 1,2-(hydrogen phosphate)
inositol 1,2-cyclic phosphate
EPITOPE ID:140425
(3ar,4r,5s,6s,7r,7as)-2,4,5,6,7-pentahydroxy-hexahydro-2h-1,3,2$l^{5}-benzodioxaphosphol-2-one
Q27103070

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
myo-inositol cyclic phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (26.67)18.7374
1990's17 (56.67)18.2507
2000's3 (10.00)29.6817
2010's2 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.01 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]